Entera Bio Stock Today

ENTX Stock  USD 1.88  0.03  1.62%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Entera Bio is trading at 1.88 as of the 17th of March 2025; that is 1.62 percent increase since the beginning of the trading day. The stock's open price was 1.85. Entera Bio has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
28th of June 2018
Category
Healthcare
Classification
Health Care
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. The company has 36.83 M outstanding shares of which 104.48 K shares are currently shorted by private and institutional investors with about 1.45 trading days to cover. More on Entera Bio

Moving against Entera Stock

  0.68IVA Inventiva SaPairCorr
  0.65KRYS Krystal BiotechPairCorr
  0.48PBH Prestige Brand HoldingsPairCorr
  0.4LLY Eli LillyPairCorr

Entera Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01120.0117
Sufficiently Down
Slightly volatile
Gross Profit Margin0.220.2463
Moderately Down
Slightly volatile
Total Current Liabilities932.8 K981.9 K
Notably Down
Very volatile
Non Current Liabilities Total246.2 K259.2 K
Notably Down
Slightly volatile
Total Assets13.9 M13.5 M
Fairly Up
Slightly volatile
Total Current Assets13 M12.9 M
Slightly Up
Slightly volatile
Debt Levels
Entera Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Entera Bio's financial leverage. It provides some insight into what part of Entera Bio's total assets is financed by creditors.
Liquidity
Entera Bio currently holds 390 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Entera Bio has a current ratio of 10.67, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Entera Bio's use of debt, we should always consider it together with its cash and equity.

Depreciation

97,288.88
Entera Bio (ENTX) is traded on NASDAQ Exchange in USA. It is located in Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002 and employs 18 people. Entera Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 69.24 M. Entera Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 36.83 M outstanding shares of which 104.48 K shares are currently shorted by private and institutional investors with about 1.45 trading days to cover. Entera Bio currently holds about 17.28 M in cash with (7.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Entera Bio Probability Of Bankruptcy
Ownership Allocation
Entera Bio holds a total of 36.83 Million outstanding shares. Entera Bio shows significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Entera Ownership Details

Entera Stock Institutional Holders

InstituionRecorded OnShares
Group One Trading, Lp2024-12-31
51.0
View Entera Bio Diagnostics

Entera Bio Historical Income Statement

At this time, Entera Bio's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 31.4 M in 2025, whereas Total Revenue is likely to drop slightly above 15.3 K in 2025. View More Fundamentals

Entera Stock Against Markets

Entera Bio Corporate Management

Hillel MBAChief OfficerProfile
Miranda MBACEO DirectorProfile
II MDChief OfficerProfile
Gregory BurshteinChief DevelopmentProfile
Dana CPAChief OfficerProfile

Additional Tools for Entera Stock Analysis

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.